Merck KGaA ADR share price logo

Merck KGaA ADR

NASDAQ: MKKGY

Large Cap

$32.32

+1.31

(+4.22%)

as on

Merck KGaA ADR Stock Performance

as on June 5, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $32.01
    $32.48
    downward going graph

    0.96%

    Downside

    0.50%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    downward going graph

    100.00%

    Downside

    -100.00%

    Upside

    downward going graph

Merck KGaA ADR share price movements today

Previous Close
$31.01
Open
$32.04
Volume
215.9K
Day's Low - High
$32.01 - $32.48

Merck KGaA ADR Historical Returns

1 Month Return
0 %
3 Month Return
0 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Merck KGaA ADR Stock Fundamentals & Key Indicators

Check Merck KGaA ADR market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$67.2B

EPS (TTM)

1.8754

Dividend Yield

1.69%

PE Ratio (TTM)

22.72

Industry PE ratio

16.151

PEG Ratio

2.5912

Return On Equity TTM

8.53%

Merck KGaA ADR Stock Valuation

Track how Merck KGaA ADR P/E has moved over time to understand its valuation trends.

Merck KGaA ADR in the last 5 years

  • Overview

  • Trends

Lowest (11.33x)

September 30, 2022

Industry (16.15x)

June 4, 2026

Today (22.72x)

June 4, 2026

Highest (25.71x)

December 31, 2021

LowHigh

Today’s Price to Earnings Ratio: 22.72x

Merck KGaA ADR vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Merck KGaA ADR with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
NA$67.2BNA22.7212.08%1.69%
BUY$23.3B212.29%20.3140.62%NA
HOLD$18.3B1.1%NA-2.04%3.04%
BUY$38.6BNA17.4415.11%2.21%
BUY$32.5B-55.71%12.7228.04%2.6599999999999997%

Merck KGaA ADR Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
5,699
5,564
5,758
5,847
5,668
5,709
5,255
5,318
5,199
5,134
Gross Profit
3,161
3,270
3,478
3,491
3,242
3,401
3,027
3,213
2,933
3,065
Operating Income
830
1,074
792
1,097
824
1,006
891
1,221
773
943
EBITDA
1,188
1,528
1,538
1,581
1,419
1,507
1,365
1,706
1,675
1,470
Interest Expense
39
74
72
89
59
78
79
126
119
104
Depreciation
507
454
680
449
551
473
457
458
910
497
Income Before Tax
641
899
785
1,043
808
956
829
1,122
397
869
Income Tax Expense
53
200
180
231
140
218
174
225
76
200
Net Income
639
754
653
898
697
794
652
902
316
659
Net Profit Margin
11.22%
13.55%
11.34%
15.36%
12.31%
13.92%
12.41%
16.96%
6.08%
12.84%

Merck KGaA ADR Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
15,836
18,134
16,876
17,948
21,326
22,255
23,527
22,901
22,134
20,269
Gross Profit
10,354
11,839
10,754
11,274
13,013
13,945
14,503
13,519
13,062
11,421
Operating Income
2,481
2,525
1,727
2,120
2,985
4,179
4,474
3,609
3,645
3,904
EBITDA
4,237
4,169
3,463
4,116
4,775
5,880
6,279
5,685
5,962
5,710
Interest Expense
342
348
339
476
387
288
203
272
292
251
Depreciation
-
1,758
1,812
1,944
1,938
1,762
2,030
1,971
2,134
2,298
Income Before Tax
2,154
2,224
1,461
1,735
2,630
3,924
4,287
3,484
3,536
3,177
Income Tax Expense
521
-386
368
440
637
859
948
650
751
665
Net Income
1,717
3,076
3,838
1,466
2,416
3,453
3,519
3,080
2,905
2,505
Net Profit Margin
10.84%
16.96%
22.74%
8.17%
11.33%
15.52%
14.96%
13.45%
13.13%
12.36%

Merck KGaA ADR Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
694
607
812
669
738
655
898
316
669
Operating Cash Flow
1,035
861
1,458
1,231
556
567
1,518
1,258
831
Investing Cash Flow
-689
-30
-1,698
-633
-419
-143
-3,116
-581
-767
Financing Cash Flow
-107
-360
727
-1,246
-1,609
-257
2,704
-198
-63
Change in Cash
238
465
476
-644
-1,512
161
1,085
487
3

Merck KGaA ADR Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
2,610
3,396
1,324
1,994
3,065
3,339
2,824
2,786
2,505
Operating Cash Flow
2,696
2,219
2,856
3,477
4,616
4,259
3,784
4,586
3,776
Investing Cash Flow
-1,147
2,191
-6,153
-1,340
-1,578
-2,743
-1,892
-3,050
-4,092
Financing Cash Flow
-1,870
-2,825
1,902
-1,522
-2,504
-1,555
-1,732
-985
603
Change in Cash
-350
1,581
-1,389
574
544
-45
128
535
520

Insights on Merck KGaA ADR

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Merck KGaA, Darmstadt, Germany American Depositary Receipts have shown positive profit trends over the last two quarters. The net profit increased from $316.00 million to $659.00 million, representing an average growth of 52.1% per quarter.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, MKKGY stock has moved up by 19.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, United Therapeutics Corporation Common Stock has given 66.8% return, outperforming this stock by 81.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Viatris Inc. Common Stock has given 83.9% return, outperforming this stock by 66.1%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Merck KGaA, Darmstadt, Germany American Depositary Receipts have seen a decline in revenue for the last three quarters. The revenue decreased from $5.31 billion to $5.13 billion, averaging a decrease of 1.7% each quarter.

About Merck KGaA ADR

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.
OrganisationMerck KGaA ADR
HeadquartersFrankfurter Strasse 250, Darmstadt, Germany, 64293
IndustryDrug Manufacturers - Specialty & Generic
CEODr. Kai Beckmann
E-voting on sharesClick here to vote

Key Management of Merck KGaA ADR

Name

Title

Ms. Helene von Roeder

CFO & Member of Executive Board

Mr. Danny Pinhas Bar-Zohar M.D.

Member of the Executive Board & CEO of Healthcare

Mr. Jean Charles Wirth

Member of the Executive Board & CEO Life Science

Ms. Khadija Ben Hammada

Member of the Executive Board & Chief People Officer

Florian Schraeder

Head of Investor Relations

Mr. Axel Lober

Head of Global Communications

Dr. Kai Beckmann

CEO & Chair of Management Board

Mr. Benjamin Hein

Member of Management Board & CEO of Electronics Business Sector

Mr. Frank Gotthardt

Head of Corporate & Government Relations - Europe

Ms. Belen Garijo Lopez M.D.

Executive Officer

FAQs

What is Merck KGaA ADR share price today?

Merck KGaA ADR share price today is $32.32 as on at the close of the market. Merck KGaA ADR share today touched a day high of $32.48 and a low of $32.01.

What is the 52 week high and 52 week low for Merck KGaA ADR share?

Merck KGaA ADR share touched a 52 week high of $0 on and a 52 week low of $0 on . Merck KGaA ADR stock price today i.e. is closed at $32.32,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Merck KGaA ADR's market capitalisation today?

Merck KGaA ADR market capitalisation is $0.07T as on .

How to invest in Merck KGaA ADR Stock (MKKGY) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Merck KGaA ADR on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Merck KGaA ADR Shares that will get you 0.0464 shares as per Merck KGaA ADR share price of $32.32 per share as on June 5, 2026 at 1:29 am IST.

What is the minimum amount required to buy Merck KGaA ADR Stock (MKKGY) from India?

Indian investors can start investing in Merck KGaA ADR (MKKGY) shares with as little as ₹95.775 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.75 in Merck KGaA ADR stock (as per the Rupee-Dollar exchange rate as on ). Based on Merck KGaA ADR share’s latest price of $32.32 as on June 5, 2026 at 1:29 am IST, you will get 0.3094 shares of Merck KGaA ADR. Learn more about fractional shares .